Details of the Drug

General Information of Drug (ID: DM1BKA6)

Drug Name

Opicapone

Synonyms

BIA-9-1067

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1]

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

413.2

Topological Polar Surface Area (xlogp)

3.4

Rotatable Bond Count (rotbonds)

2

Hydrogen Bond Donor Count (hbonddonor)

2

Hydrogen Bond Acceptor Count (hbondacc)

8

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [2]
Bioavailability: The bioavailability of drug is 64% [2]
Clearance: The total body clearance of drug is 22 L/h [3]
Elimination: Following administration of a single 100 mg dose of radiolabeled opicapone in healthy subjects, about 70% of the total dose was recovered in feces, where 22% of the recovered dose was excreted as an unchanged parent drug [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 61.6 hours [4]
Vd: The volume of distribution (Vd) of drug is 29 L [3]

Chemical Identifiers

Formula: C15H10Cl2N4O6
IUPAC Name: 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol
Canonical SMILES: CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-]
InChI: InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3
InChIKey: ASOADIZOVZTJSR-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 135565903
ChEBI ID: CHEBI:134699
CAS Number: 923287-50-7
DrugBank ID: DB11632
TTD ID: D01SGK
ACDINA ID: D01302

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Catechol-O-methyl-transferase (COMT)	TTKWFB8	COMT_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Parkinson disease

ICD Disease Classification

8A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Catechol-O-methyl-transferase (COMT)	DTT	COMT	9.24E-02	0.17	1.09

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Opicapone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Opicapone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[15]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Opicapone and Esketamine.	Depression [6A70-6A7Z]	[16]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Opicapone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[17]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Opicapone and Lasmiditan.	Migraine [8A80]	[18]
-----------

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Erythrosine sodium anhydrous	E00324	27872	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Amaranth	E00228	13506	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Gelatin	E00630	Not Available	Other agent
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Opicapone 50 mg capsule	50 mg	Capsule	Oral
Opicapone 25 mg capsule	25 mg	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	FDA Approved Drug Products: Pifeltro (doravirine) oral tablets
3	Summary of Product Characteristics: Ongentys (opicapone) oral capsules
4	FDA Approved Drug Products: ONGENTYS (opicapone) capsules, for oral use
5	Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771.
6	Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
7	Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52.
8	Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor. Bioconjug Chem. 2002 Sep-Oct;13(5):1112-8.
9	CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):305-11.
10	Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol. 1990 Oct;13(5):436-47.
11	Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010 Sep;122(1-3):1-23.
12	Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2004 Dec 2;47(25):6207-17.
13	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
14	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
15	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
16	Cerner Multum, Inc. "Australian Product Information.".
17	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
18	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.